Gene Cloning Services Market is Led by the Gene Therapy Category

The value of the gene cloning services market is about USD 3,154.1 million in 2023, which will touch a value of USD 10,019.6 million by 2030, powering at a compound annual growth rate of 18.1% by the end of this decade.

The rising occurrence of chronic diseases, growing demand for precision medicine, and substantial incidence of inherited conditions will contribute to the industry growth. Moreover, the substantial rise in research in the medical field because of the surge in the spending by governments, development of the biotech industry, and tech progressions in genetics will boost the industry in the future.

The gene therapy category leads the industry with a share of 35% in 2023. This is credited to the fact that such a therapy can cure infections or ailments that were previously considered incurable. Scientists and researchers have identified over 50,000 inherited ailments caused by mutations in a single gene. With a profound understanding of protein pathways and gene expression, more treatments can be tested and established effective for people.

North America gene cloning services market had the largest share, of about 55%, in 2023. This is because of the considerable R&D activities in the biotech and pharma sectors in this region. Moreover, the high occurrence of chronic ailment, existence of a strong healthcare system, and substantial acceptance of cutting-edge technologies are contributing to the growth of the industry.

The cases of people suffering from hereditary conditions is on the rise at a global level, and this will power the demand for gene cloning services. This trend will continue in the years to come as well.

Read More

How is growing R&D investments in Drug Discovery and Development Driving Synthetic Biology Market?

The need for advanced and innovative drug discovery and development has increased considerably as the prevalence of various diseases, such as neurological disorders, immunological disorders, infectious diseases, and cancer is rising. Due to this, several biopharmaceutical and pharmaceutical companies are becoming more inclined toward the development of new and more effective biopharmaceutical drugs. This in turn, has been made possible because of the growing research and development investments in drug discovery and development. Since synthetic biology provides innovative solutions for drug discovery, its demand is surging as well. Using synthetic biology, living organisms are genetically developed for required functions in research laboratories. The field derives input from molecular and cell biology, biochemistry, bioinformatics, mathematics, and evolutionary systematics. Synthetic biology elucidates disease mechanisms and target identification, along with providing avenues to design and discover novel biopharmaceuticals and small chemotherapeutic molecules.

According to a research conducted by the P&S Intelligence, the global synthetic biology market is expected to generate a revenue of $23.8 billion and advance at a CAGR of 35.4% in the near future. Among several reasons for the growth of this market is the increasing geriatric population. According to the United Nations Department of Economic and Social Affairs, the population of people aged 60 years and above is rising at a high rate; the number rose from 9.2% in 1990 to 11.7% in 2013 and is further predicted to reach 21.1% by 2050. People aged 60 years and above are more prone to illness because of low immunity and metabolic rate, due to which diseases such as cancer and immunological diseases affect elderly people more severely. The treatment of such diseases requires more effective biotherapeutics and synthetic biology helps achieve the same by enabling designing of novel strategies for the treatment as well as production of cheap drugs.

Lean more About this Report at: http://bit.ly/2MyTQqa

The segments of the field of synthetic biology are technology and tool. Among these, synthetic biology technology was the most in demand during 2011–2014. Synthetic biology has become more significant due to the utilization of several innovative and advanced technologies which are used in the field of life sciences for developing biological systems and bio-based products, designing, and redesigning. The two foundational technologies applied by synthetic biology are DNA synthesis and DNA sequencing. DNA synthesis provides the ability to design new, synthetic biological systems and parts and DNA sequencing helps understand the components of natural biological systems. Synthetic biology technology is further bifurcated into enabling and enabled.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synthetic-biology-market

Geographically, North America dominated the global market, among all the regions in 2014; and it is expected to grow with a CAGR of 35.2% during the period 2015 – 2020. However, the Asian market is expected to witness fastest growth, with a CAGR of 39.8% during the forecast period.

The key companies operating in the global synthetic biology market include E. I. du PONT de Nemours and Company, Amyris Inc., GenScript USA Inc., Intrexon Corporation, Thermo Fisher Scientific Inc., Synthetic Genomics Inc., Royal DSM, Novozymes A/S, New England Biolabs Inc., and Integrated DNA Technologies Inc.

Read More